Granules in the improvement of oral heparin bioavailability (original) (raw)

Oral bioavailability of a low molecular weight heparin using a polymeric delivery system

Philippe Maincent

Journal of Controlled Release, 2006

View PDFchevron_right

Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer

Mitchell Wachtel

Drug Development Research, 2006

View PDFchevron_right

Oral heparin: status review

Shingai Majuru

Thrombosis journal, 2006

View PDFchevron_right

Recent advances in search of oral heparin therapeutics

Dr. Shivani Rai Paliwal

Medicinal Research Reviews, 2012

View PDFchevron_right

Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations

Maciej Dryjski

British Journal of Clinical Pharmacology, 1989

View PDFchevron_right

Encapsulation of low molecular weight heparins: Influence on the anti-Xa/anti-IIa ratio

Philippe Maincent

Journal of Controlled Release, 2009

View PDFchevron_right

Novel Nanoparticles for the Oral Delivery of Low Molecular Weight Heparin: In Vitro and in Vivo Assessment

Umamahesh Balekari

Asian Journal of Pharmaceutical and Clinical Research, 2017

View PDFchevron_right

Pharmacokinetics and Pharmacodynamics of Oral Heparin Solid Dosage Form in Healthy Human Subjects

Fuming Zhang

2000

View PDFchevron_right

Preparation and In Vitro Evaluation of Heparin-Loaded Polymeric Nanoparticles

P. Maincent

Drug Delivery, 2001

View PDFchevron_right

The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin

Kun-ju Lin

Biomaterials, 2009

View PDFchevron_right

Pharmacokinetics of a low molecular weight heparin compared with standard heparin

Thomas Mätzsch

Thrombosis Research, 1986

View PDFchevron_right

Strategies to Overcome Heparins’ Low Oral Bioavailability

Madalena Pinto

Pharmaceuticals, 2016

View PDFchevron_right

Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation

Vaishali Bagalkot

Thrombosis Research, 2006

View PDFchevron_right

Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis

Giangiacomo Torri

Journal of Thrombosis and Haemostasis

View PDFchevron_right

Oral low molecular weight heparin delivery by microparticles from complex coacervation

Philippe Maincent

European Journal of Pharmaceutics and Biopharmaceutics, 2007

View PDFchevron_right

Supersulfated" heparin fragments, a new type of low-molecular weight heparin. Physico-chemical and pharmacological properties

Giangiacomo Torri

Biochemical Pharmacology

View PDFchevron_right

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin

Monika Kujdowicz

PLOS ONE, 2015

View PDFchevron_right

Structure and Activity of a New Low-Molecular-Weight Heparin Produced by Enzymatic Ultrafiltration

Fuming Zhang

Journal of Pharmaceutical Sciences, 2014

View PDFchevron_right

Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally

Denis Barritault

Journal of Biomedical Materials Research Part A, 2007

View PDFchevron_right

N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects

Job Harenberg

Thrombosis Research, 1995

View PDFchevron_right

Homogeneous low-molecular-weight heparins with reversible anticoagulant activity

truong pham

Nature Chemical Biology, 2014

View PDFchevron_right

Chemical composition, particle size range, and biological activity of some low molecular weight heparin derivatives

Paul Rochon

Journal of Pharmaceutical Sciences, 1990

View PDFchevron_right

Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers

Thomas Mätzsch

Thrombosis Research, 1991

View PDFchevron_right

Evaluation of the in vitro and in vivo therapeutic equivalence of two pharmaceutically equivalent heparin products

Yasser Bustanji

2011

View PDFchevron_right

“Supersulfated” heparin fragments, a new type of low-molecular weight heparin

Giangiacomo Torri

Biochemical Pharmacology, 1987

View PDFchevron_right

Chemical Microdetermination of Heparin in Plasma

T. Toida

Analytical Biochemistry, 1997

View PDFchevron_right

Comparison of low-molecular weight heparins to unfractionated heparin

Robert Berent

European Heart Journal, 2001

View PDFchevron_right

Recommendations on biosimilar low-molecular-weight heparins

J. Harenberg, Benito Casu, Frederick Ofosu

Journal of Thrombosis and Haemostasis, 2009

View PDFchevron_right

In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits

P. Maincent

Circulation, 2002

View PDFchevron_right

Low-Molecular-Weight Heparins: Are they all the Same?

Jeffrey Ginsberg

British Journal of Haematology, 2003

View PDFchevron_right

Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation

Dr. Shivani Rai Paliwal

International journal of pharmaceutics, 2012

View PDFchevron_right

Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin

Sultan Nacak Baytas

Journal of Medicinal Chemistry, 2021

View PDFchevron_right

Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)—A three way cross-over study in healthy volunteers

Jordi Fontcuberta

Thrombosis Research, 1995

View PDFchevron_right

NOVEL SUBCUTANEOUS SUSTAINED RELEASE NANOPARTICLES ENCAPSULATING LOW MOLECULAR WEIGHT HEPARIN (LMWH): PREPARATION, CHARACTERIZATION AND EVALUATION Original Article

International Journal of Pharmacy and Pharmaceutical Sciences (IJPPS)

International Journal of Pharmacy and Pharmaceutical Sciences, 2016

View PDFchevron_right

Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?

Ludovic Drouet

Targeted Oncology, 2012

View PDFchevron_right